Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sarepta Pressured FDA On Eteplirsen Due To ‘Dire’ Finances, Gave Investors Rosier Picture

Nov 04 2016

• By Derrick Gingery

Related Content

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

Sep 20 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

FDA's Fears Realized: Sponsors Pitching Investors 'Sarepta Model'

Oct 26 2016

Duchenne Muscular Dystrophy: Second Product Isn't The Charm

Jan 15 2016

Sarepta's Duchenne Treatment Likely Making Progress At FDA

Feb 08 2016

Political Appointees Shouldn't Influence Approval Decisions, Califf Says

Oct 20 2016

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

Accelerated Approval Should Be Less 'Wide Open,' Califf Says

Oct 20 2016

Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template

Oct 15 2016

Priority Review Politics: With Two Pending DMD Products, FDA Still Faces Community Anxiety

Aug 18 2016

Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales

Sep 23 2016

Related Companies

Sarepta Therapeutics, Inc.

BioMarin Pharmaceutical Inc.

Additional Topics

United States Approvals Clinical Trials Regulation Drug Approval Standards Financing Rare Diseases Neurology BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window